GABAvsVitamin D3

GABA binds to GABA-A receptors (ligand-gated Cl- channels with alpha1-6, beta1-3, gamma1-3 subunits) and GABA-B receptors (G-protein coupled, Gi/o mediated), reducing neuronal excitability through hyperpolarization. However, supplemental GABA has limited blood-brain barrier penetration due to absence of a dedicated transporter and rapid metabolism by GABA-transaminase and succinate semialdehyde dehydrogenase in periphery. The calming effects may be mediated through: (1) GABA-A and GABA-B receptors in the enteric nervous system (gut-brain axis) — vagal afferents project to the nucleus tractus solitarius and influence limbic regions; (2) small amounts crossing the BBB via paracellular leakage or in individuals with compromised barrier integrity; (3) peripheral effects reducing systemic stress markers (cortisol, heart rate variability). PharmaGABA (Lactobacillus fermentation product) may have better absorption via peptide-like transport or different pharmacokinetics.

Vitamin D (1,25-dihydroxyvitamin D3) crosses the blood-brain barrier and binds to vitamin D receptors (VDR), a nuclear receptor expressed on neurons, astrocytes, microglia, and oligodendrocytes. VDR heterodimerizes with RXR and binds vitamin D response elements (VDREs) to regulate transcription. It upregulates neurotrophic factors: GDNF (glial cell line-derived), NGF, NT-3 via CREB and other transcription factors. Vitamin D promotes serotonin synthesis by upregulating tryptophan hydroxylase 2 (TPH2) and dopamine synthesis via tyrosine hydroxylase. It reduces neuroinflammation by suppressing microglial IL-1beta, TNF-alpha, and iNOS, and supports calcium homeostasis via regulation of L-type voltage-gated calcium channels and calbindin-D28k. Vitamin D regulates over 200 genes including those for neuroprotection, synaptic plasticity, and myelination.